{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,1,14]],"date-time":"2026-01-14T08:13:05Z","timestamp":1768378385028,"version":"3.49.0"},"reference-count":52,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2025,12,9]],"date-time":"2025-12-09T00:00:00Z","timestamp":1765238400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2026,1,13]],"date-time":"2026-01-13T00:00:00Z","timestamp":1768262400000},"content-version":"vor","delay-in-days":35,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["BMC Prim. Care"],"DOI":"10.1186\/s12875-025-03125-0","type":"journal-article","created":{"date-parts":[[2025,12,9]],"date-time":"2025-12-09T10:57:30Z","timestamp":1765277850000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["The use of triptans and other acute treatments for the management of migraine in routine clinical practice in England: a retrospective cohort study using the Clinical Practice Research Datalink (CPRD)"],"prefix":"10.1186","volume":"27","author":[{"given":"Shuk-Li","family":"Collings","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Amisha","family":"Patel","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hannah","family":"Gowman","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sarah","family":"Law","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Aideen","family":"Ahern","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Robert","family":"Pawinski","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Robert","family":"Wood","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Shazia K.","family":"Afridi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2025,12,9]]},"reference":[{"key":"3125_CR1","unstructured":"Steinmetz JD, Seeher KM, Schiess N, Nichols E, Cao B, Servili C, et al. Global, regional,and national burden of disorders affecting the nervous system, 1990\u20132021: a systematic analysis for the Global Burden of Disease Study 2021. The Lancet Neurology.2024;23(4):344\u2009\u2013\u200981."},{"issue":"7","key":"3125_CR2","doi-asserted-by":"publisher","first-page":"519","DOI":"10.1046\/j.1468-2982.2003.00568.x","volume":"23","author":"T Steiner","year":"2003","unstructured":"Steiner T, Scher A, Stewart W, Kolodner K, Liberman J, Lipton R. The prevalence and disability burden of adult migraine in England and their relationships to age, gender and ethnicity. Cephalalgia. 2003;23(7):519\u201327.","journal-title":"Cephalalgia"},{"issue":"1","key":"3125_CR3","doi-asserted-by":"publisher","first-page":"254","DOI":"10.1186\/s12889-024-21244-8","volume":"25","author":"G Coppola","year":"2025","unstructured":"Coppola G, Brown JD, Mercadante AR, Drakeley S, Sternbach N, Jenkins A, et al. The epidemiology and unmet need of migraine in five European countries: results from the National health and wellness survey. BMC Public Health. 2025;25(1):254.","journal-title":"BMC Public Health"},{"issue":"547","key":"3125_CR4","doi-asserted-by":"publisher","first-page":"102","DOI":"10.3399\/bjgp08X264072","volume":"58","author":"D Kernick","year":"2008","unstructured":"Kernick D, Stapley S, Hamilton W. GPs\u2019 classification of headache: is primary headache underdiagnosed? Br J Gen Pract. 2008;58(547):102\u20134.","journal-title":"Br J Gen Pract"},{"key":"3125_CR5","unstructured":"The Migraine Trust. What is the impact of migraine in the UK? Accessed 14. January 2025. [Available from: https:\/\/migrainetrust.org\/wp-content\/uploads\/2021\/08\/State-of-the-Migraine-Nation-impact-rapid-review.pdf] . 2020."},{"key":"3125_CR6","doi-asserted-by":"publisher","first-page":"221","DOI":"10.1111\/head.12601","volume":"55","author":"C Cameron","year":"2015","unstructured":"Cameron C, Kelly S, Hsieh SC, Murphy M, Chen L, Kotb A, et al. Triptans in the acute treatment of migraine: a systematic review and network meta-analysis. Headache: The Journal of Head and Face Pain. 2015;55:221\u201335.","journal-title":"Headache: The Journal of Head and Face Pain"},{"issue":"1","key":"3125_CR7","doi-asserted-by":"publisher","first-page":"250","DOI":"10.3390\/ijerph18010250","volume":"18","author":"M Leonardi","year":"2021","unstructured":"Leonardi M, Grazzi L, D\u2019Amico D, Martelletti P, Guastafierro E, Toppo C, et al. Global burden of headache disorders in children and adolescents 2007\u20132017. Int J Environ Res Public Health. 2021;18(1):250.","journal-title":"Int J Environ Res Public Health"},{"key":"3125_CR8","unstructured":"National Institute for Health and Care Excellence (NICE). Migraine: Drugs for acute migraine. [Updated November 2024]. Accessed 20. December 2024. 2024 [Available from: https:\/\/cks.nice.org.uk\/topics\/migraine\/prescribing-information\/drugs-for-acute-migraine\/."},{"issue":"1","key":"3125_CR9","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1186\/s10194-016-0703-0","volume":"17","author":"H Xu","year":"2016","unstructured":"Xu H, Han W, Wang J, Li M. Network meta-analysis of migraine disorder treatment by NSAIDs and triptans. J Headache Pain. 2016;17(1):1\u201318.","journal-title":"J Headache Pain"},{"issue":"10","key":"3125_CR10","doi-asserted-by":"publisher","first-page":"e2128544","DOI":"10.1001\/jamanetworkopen.2021.28544","volume":"4","author":"C-P Yang","year":"2021","unstructured":"Yang C-P, Liang C-S, Chang C-M, Yang C-C, Shih P-H, Yau Y-C, et al. Comparison of new pharmacologic agents with triptans for treatment of migraine: a systematic review and meta-analysis. JAMA Netw Open. 2021;4(10):e2128544-e.","journal-title":"JAMA Netw Open"},{"issue":"6","key":"3125_CR11","doi-asserted-by":"publisher","first-page":"555","DOI":"10.1080\/13543784.2019.1618830","volume":"28","author":"A Negro","year":"2019","unstructured":"Negro A, Martelletti P. Gepants for the treatment of migraine. Expert Opin Investig Drugs. 2019;28(6):555\u201367.","journal-title":"Expert Opin Investig Drugs"},{"key":"3125_CR12","unstructured":"National Institute for Health and Care Excellence (NICE). Scenario: Migraine in adults. Accessed 17. October 2024. [Available from: https:\/\/cks.nice.org.uk\/topics\/migraine\/management\/adults\/#criteria-for-preventive-treatment] . 2024."},{"issue":"8","key":"3125_CR13","doi-asserted-by":"publisher","first-page":"501","DOI":"10.1038\/s41582-021-00509-5","volume":"17","author":"AK Eigenbrodt","year":"2021","unstructured":"Eigenbrodt AK, Ashina H, Khan S, Diener H-C, Mitsikostas DD, Sinclair AJ, et al. Diagnosis and management of migraine in ten steps. Nat Rev Neurol. 2021;17(8):501\u201314.","journal-title":"Nat Rev Neurol"},{"key":"3125_CR14","unstructured":"British Association for the Study of Headache (BASH). National Headache Management System for Adults. Accessed 14. January 2025. [Available from: https:\/\/bash.org.uk\/wp-content\/uploads\/2023\/02\/01_BASHNationalHeadache_Management_SystemforAdults_2019_guideline_versi.pdf] . 2019."},{"issue":"23","key":"3125_CR15","doi-asserted-by":"publisher","first-page":"2357","DOI":"10.1001\/jama.2021.7939","volume":"325","author":"JH VanderPluym","year":"2021","unstructured":"VanderPluym JH, Singh RBH, Urtecho M, Morrow AS, Nayfeh T, Roldan VDT, et al. Acute treatments for episodic migraine in adults: a systematic review and meta-analysis. JAMA. 2021;325(23):2357\u201369.","journal-title":"JAMA"},{"key":"3125_CR16","unstructured":"NHS England, Migraine. October. Accessed 17 2024. [Available from: https:\/\/www.nhs.uk\/conditions\/migraine\/]. 2022."},{"key":"3125_CR17","unstructured":"Scottish Intercollegiate Guidelines Network (SIGN). SIGN155. Pharmacological management of migraine. Quick reference guide. Accessed 17. October 2024. 2018 [updated March 2023. Available from: https:\/\/www.sign.ac.uk\/media\/2066\/sign-155-qrg-2023-update-0-2.pdf."},{"issue":"2","key":"3125_CR18","doi-asserted-by":"publisher","first-page":"98","DOI":"10.1111\/j.1468-2982.2005.01010.x","volume":"26","author":"CG Dahl\u00f6f","year":"2006","unstructured":"Dahl\u00f6f CG. Infrequent or non-response to oral Sumatriptan does not predict response to other triptans\u2013review of four trials. Cephalalgia. 2006;26(2):98\u2013106.","journal-title":"Cephalalgia"},{"key":"3125_CR19","unstructured":"National Institute of Health and Care Excellence (NICE). Rimegepant for treating migraine. Technology appraisal guidance [TA919]. Accessed 18. October 2023. [Avaliable from: https:\/\/www.nice.org.uk\/guidance\/ta919] . 2023."},{"issue":"5","key":"3125_CR20","doi-asserted-by":"publisher","first-page":"437","DOI":"10.1177\/0333102420905307","volume":"40","author":"RB Lipton","year":"2020","unstructured":"Lipton RB, Marcus SC, Shewale AR, Dodick DW, Viswanathan HN, Doshi JA. Acute treatment patterns in patients with migraine newly initiating a triptan. Cephalalgia. 2020;40(5):437\u201347.","journal-title":"Cephalalgia"},{"issue":"1","key":"3125_CR21","doi-asserted-by":"publisher","first-page":"41","DOI":"10.1186\/s10194-020-01110-9","volume":"21","author":"L Lombard","year":"2020","unstructured":"Lombard L, Farrar M, Ye W, Kim Y, Cotton S, Buchanan AS, et al. A global real-world assessment of the impact on health-related quality of life and work productivity of migraine in patients with insufficient versus good response to triptan medication. J Headache Pain. 2020;21(1):41.","journal-title":"J Headache Pain"},{"issue":"1","key":"3125_CR22","doi-asserted-by":"publisher","first-page":"425","DOI":"10.1186\/s12883-021-02451-x","volume":"21","author":"AM Deighton","year":"2021","unstructured":"Deighton AM, Harris LA, Johnston K, Hogan S, Quaranta LA, L\u2019Italien G, et al. The burden of medication overuse headache and patterns of switching and discontinuation among triptan users: a systematic literature review. BMC Neurol. 2021;21(1):425.","journal-title":"BMC Neurol"},{"key":"3125_CR23","unstructured":"The Migraine Trust. Medication overuse headache. Accessed 20. December 2024. [Available from: https:\/\/migrainetrust.org\/understand-migraine\/types-of-migraine\/medication-overuse-headache\/."},{"issue":"7","key":"3125_CR24","doi-asserted-by":"publisher","first-page":"e0130733","DOI":"10.1371\/journal.pone.0130733","volume":"10","author":"JL Jackson","year":"2015","unstructured":"Jackson JL, Cogbill E, Santana-Davila R, Eldredge C, Collier W, Gradall A, et al. A comparative effectiveness meta-analysis of drugs for the prophylaxis of migraine headache. PLoS One. 2015;10(7):e0130733.","journal-title":"PLoS One"},{"issue":"9","key":"3125_CR25","doi-asserted-by":"publisher","first-page":"1225","DOI":"10.1007\/s11606-013-2433-1","volume":"28","author":"TA Shamliyan","year":"2013","unstructured":"Shamliyan TA, Choi J-Y, Ramakrishnan R, Miller JB, Wang S-Y, Taylor FR, et al. Preventive pharmacologic treatments for episodic migraine in adults. J Gen Intern Med. 2013;28(9):1225\u201337.","journal-title":"J Gen Intern Med"},{"key":"3125_CR26","unstructured":"National Institute for Health and Care Excellence (NICE). Eptinezumab for preventing migraine. Technology appraisal guidance [TA871]. Accessed 01. May 2025. [Available from: https:\/\/www.nice.org.uk\/guidance\/ta871] . 2023."},{"key":"3125_CR27","unstructured":"National Institute for Health and Care Excellence (NICE). Fremanezumab for preventing migraine. Technology appraisal guidance [TA764]. Accessed 01. May 2025. [Available from: https:\/\/www.nice.org.uk\/guidance\/ta764] . 2022."},{"key":"3125_CR28","unstructured":"National Institute for Health and Care Excellence (NICE). Erenumab for preventing migraine. Technology appraisal guidance [TA682]. Accessed 01. May 2025. [Available from: https:\/\/www.nice.org.uk\/guidance\/ta682] . 2021."},{"key":"3125_CR29","unstructured":"National Institute for Health and Care Excellence (NICE). Galcanezumab for preventing migraine. Technology appraisal guidance [TA659]. Accessed 01. May 2025. [Available from: https:\/\/www.nice.org.uk\/guidance\/ta659] . 2020."},{"key":"3125_CR30","unstructured":"National Institute for Health and Care Excellence (NICE). Technology appraisal guidance [TA260]. Botulinum Toxin Type A for the Prevention of Headaches in Adults with Chronic Migraine. Accessed 14. February 2025. 2012 [Available from: https:\/\/www.nice.org.uk\/Guidance\/ta260."},{"issue":"2","key":"3125_CR31","doi-asserted-by":"publisher","first-page":"127","DOI":"10.1177\/1756285616677005","volume":"10","author":"CM Escher","year":"2017","unstructured":"Escher CM, Paracka L, Dressler D, Kollewe K. Botulinum toxin in the management of chronic migraine: clinical evidence and experience. Ther Adv Neurol Disord. 2017;10(2):127\u201335.","journal-title":"Ther Adv Neurol Disord"},{"key":"3125_CR32","unstructured":"National Institute of Health and Care Excellence (NICE). Atogepant for preventing migraine. Technology appraisal guidance [TA973]. Accessed 27. February 2025. [Available from: https:\/\/www.nice.org.uk\/guidance\/ta973] . 2024."},{"key":"3125_CR33","unstructured":"National Institute for Health and Care Excellence (NICE). Rimegepant for preventing migraine. Technology appraisal guidance [TA906]. Accessed 01. May 2025. [Available from: https:\/\/www.nice.org.uk\/guidance\/ta906] . 2023."},{"key":"3125_CR34","unstructured":"National Institute for Health and Care Excellence (NICE). Headaches in over 12s: diagnosis and management. Clinical guideline [CG150]. Published 19 September 2012. Accessed 8 December 2024. [Available from: https:\/\/www.nice.org.uk\/guidance\/cg150] . 2021."},{"issue":"1","key":"3125_CR35","doi-asserted-by":"publisher","first-page":"86","DOI":"10.1186\/s10194-019-1034-8","volume":"20","author":"C Ziegeler","year":"2019","unstructured":"Ziegeler C, Brauns G, J\u00fcrgens TP, May A. Shortcomings and missed potentials in the management of migraine patients - experiences from a specialized tertiary care center. J Headache Pain. 2019;20(1):86.","journal-title":"J Headache Pain"},{"issue":"3","key":"3125_CR36","doi-asserted-by":"publisher","first-page":"589","DOI":"10.1007\/s40122-024-00589-3","volume":"13","author":"S Evers","year":"2024","unstructured":"Evers S, Dell\u2019Agnello G, Novick D, Gonderten HS, Panni T, Pascual J. Acute treatment patterns, migraine burden, and healthcare resource use in people with migraine: results from the OVERCOME (EU) observational study. Pain Ther. 2024;13(3):589\u2013607.","journal-title":"Pain Ther"},{"key":"3125_CR37","unstructured":"The Migraine Trust. State of the Migraine Nation Dismissed for too long: Recommendations to improve migraine care in the UK. 2021. Accessed 17 October 2024. Available from: [https:\/\/migrainetrust.org\/wp-content\/uploads\/2021\/09\/Dismissed-for-too-long_Recommendations-to-improve-migraine-care-in-the-UK.pdf]."},{"issue":"1","key":"3125_CR38","doi-asserted-by":"publisher","first-page":"91","DOI":"10.1007\/s10654-018-0442-4","volume":"34","author":"S Padmanabhan","year":"2019","unstructured":"Padmanabhan S, Carty L, Cameron E, Ghosh RE, Williams R, Strongman H. Approach to record linkage of primary care data from clinical practice research datalink to other health-related patient data: overview and implications. Eur J Epidemiol. 2019;34(1):91\u20139.","journal-title":"Eur J Epidemiol"},{"key":"3125_CR39","doi-asserted-by":"publisher","unstructured":"Clinical Practice Research Datalink (CPRD). CPRD Aurum May 2022 (Version 2022.05.001) [Data set]. [Available from: https:\/\/doi.org\/10.48329\/t89s-kf12] . 2022.","DOI":"10.48329\/t89s-kf12"},{"issue":"6","key":"3125_CR40","doi-asserted-by":"publisher","first-page":"1740","DOI":"10.1093\/ije\/dyz034","volume":"48","author":"A Wolf","year":"2019","unstructured":"Wolf A, Dedman D, Campbell J, Booth H, Lunn D, Chapman J, et al. Data resource profile: clinical practice research datalink (CPRD) aurum. Int J Epidemiol. 2019;48(6):1740\u2013g.","journal-title":"Int J Epidemiol"},{"issue":"1","key":"3125_CR41","doi-asserted-by":"publisher","first-page":"3","DOI":"10.1186\/s12963-023-00302-0","volume":"21","author":"SI Shiekh","year":"2023","unstructured":"Shiekh SI, Harley M, Ghosh RE, Ashworth M, Myles P, Booth HP, et al. Completeness, agreement, and representativeness of ethnicity recording in the united kingdom\u2019s clinical practice research datalink (CPRD) and linked hospital episode statistics (HES). Popul Health Metrics. 2023;21(1):3.","journal-title":"Popul Health Metrics"},{"key":"3125_CR42","doi-asserted-by":"publisher","unstructured":"Clinical Practice Research Datalink. CPRD Aurum ONS deaths data January 2022. [Available from: https:\/\/doi.org\/10.48329\/q34f-f505] . 2022.","DOI":"10.48329\/q34f-f505"},{"key":"3125_CR43","unstructured":"Clinical Practice Research Datalink (CPRD). Small area level data based on practice postcode - Documentation and Data Dictionary. [Available from: https:\/\/cprd.com\/sites\/default\/files\/2022-05\/Documentation_SmallAreaData_Practice_set22_v3.4_1.pdf] . 2022."},{"key":"3125_CR44","unstructured":"Patient. January. Migraine and combined hormonal contraception. Accessed 02 2025. 2021 [Available from: https:\/\/patient.info\/brain-nerves\/migraine-leaflet\/migraine-and-combined-hormonal-contraception."},{"key":"3125_CR45","unstructured":"NHS England. About Sumatriptan. Accessed 14 February 2025. 2022 [Available from: https:\/\/www.nhs.uk\/medicines\/sumatriptan\/about-sumatriptan\/."},{"issue":"1","key":"3125_CR46","doi-asserted-by":"publisher","first-page":"133","DOI":"10.1186\/s10194-022-01502-z","volume":"23","author":"S Sacco","year":"2022","unstructured":"Sacco S, Lampl C, Amin FM, Braschinsky M, Deligianni C, Ulud\u00fcz D, et al. European headache federation (EHF) consensus on the definition of effective treatment of a migraine attack and of Triptan failure. J Headache Pain. 2022;23(1):133.","journal-title":"J Headache Pain"},{"key":"3125_CR47","unstructured":"Nicolas S, Nicolas D. Triptans. In: StatPearls [Internet]: treasure Island (FL): StatPearls Publishing; [Updated 2024 Feb 25]."},{"issue":"4","key":"3125_CR48","doi-asserted-by":"publisher","first-page":"433","DOI":"10.1007\/s10198-013-0516-x","volume":"15","author":"M Hens","year":"2014","unstructured":"Hens M, Villaverde-Hueso A, Alonso V, Abaitua I, Posada de la Paz M. Comparative cost-effectiveness analysis of oral Triptan therapy for migraine in four European countries. Eur J Health Econ. 2014;15(4):433\u20137.","journal-title":"Eur J Health Econ"},{"key":"3125_CR49","doi-asserted-by":"publisher","first-page":"100053","DOI":"10.1016\/j.medidd.2020.100053","volume":"7","author":"D Moreno-Ajona","year":"2020","unstructured":"Moreno-Ajona D, P\u00e9rez-Rodr\u00edguez A, Goadsby PJ. Small-molecule CGRP receptor antagonists: A new approach to the acute and preventive treatment of migraine. Med Drug Discovery. 2020;7:100053.","journal-title":"Med Drug Discovery"},{"issue":"2","key":"3125_CR50","doi-asserted-by":"publisher","first-page":"333102422114168","DOI":"10.1177\/03331024221141686","volume":"43","author":"RB Lipton","year":"2023","unstructured":"Lipton RB, Blumenfeld A, Jensen CM, Croop R, Thiry A, L\u2019Italien G, et al. Efficacy of Rimegepant for the acute treatment of migraine based on Triptan treatment experience: pooled results from three phase 3 randomized clinical trials. Cephalalgia. 2023;43(2):3331024221141686.","journal-title":"Cephalalgia"},{"key":"3125_CR51","unstructured":"NHS England DCCP. January. Responsibility for prescribing between Primary & Secondary\/Tertiary Care. Accessed 14 2025. 2018 [Available from: https:\/\/www.england.nhs.uk\/wp-content\/uploads\/2018\/03\/responsibility-prescribing-between-primary-secondary-care-v2.pdf."},{"issue":"9","key":"3125_CR52","doi-asserted-by":"publisher","first-page":"856","DOI":"10.1111\/j.1526-4610.2004.04167.x","volume":"44","author":"SJ Tepper","year":"2004","unstructured":"Tepper SJ, Dahl\u00f6f CG, Dowson A, Newman L, Mansbach H, Jones M, et al. Prevalence and diagnosis of migraine in patients consulting their physician with a complaint of headache: data from the landmark study. Headache. 2004;44(9):856\u201364.","journal-title":"Headache"}],"container-title":["BMC Primary Care"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12875-025-03125-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s12875-025-03125-0","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12875-025-03125-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,1,14]],"date-time":"2026-01-14T03:04:31Z","timestamp":1768359871000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1186\/s12875-025-03125-0"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,12,9]]},"references-count":52,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2026,12]]}},"alternative-id":["3125"],"URL":"https:\/\/doi.org\/10.1186\/s12875-025-03125-0","relation":{},"ISSN":["2731-4553"],"issn-type":[{"value":"2731-4553","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,12,9]]},"assertion":[{"value":"26 June 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"18 November 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"9 December 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The present research was conducted in accordance with relevant guidelines and regulations. Clinical Practice Research Datalink (CPRD) has NHS Health Research Authority (HRA) Research Ethics Committee (REC) approval to allow the collection and release of anonymised primary care data for observational research [NHS HRA REC reference number: 21\/EM\/0265]. Each year CPRD obtains Section 251 regulatory support through the HRA Confidentiality Advisory Group (CAG), to enable patient identifiers, without accompanying clinical data, to flow from CPRD contributing GP practices in England to NHS Digital, for the purposes of data linkage. This study was approved by CPRD\u2019s Research Data Governance Process (protocol reference ID: 22_002459, approved 17 January 2023) and no direct subject contact or primary collection of individual human subject data occurred. Linked pseudonymised data were provided for this study by CPRD. Data were linked by NHS Digital, the statutory trusted third party for linking data, using identifiable data held only by NHS Digital. Select general practices consent to this process at a practice level, with individual patients having the right to opt out.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not applicable.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"AA, RP and SC are employees of Pfizer Ltd. AP, HG, SL are employees of Adelphi Real World, the company received funding from Pfizer Ltd to conduct this study. RW was an employee of Adelphi Real World at the time of study design and analysis. SA was paid by Pfizer Ltd for clinical advice.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"9"}}